Brief: Bayer Says Bluerock Therapeutics' Investigational Cell Therapy Lemiretprocel (Opct-001) Granted Orphan Drug FDA, EMA Designations
30/09/2026 07:34
BRIEF-Bayer Says Bluerock Therapeutics' Investigational Cell Therapy Lemiretprocel (Opct-001) Granted Orphan Drug FDA, EMA Designations Sept 30 (Reuters) - BAYER AG BAYGn.DE:
BLUEROCK THERAPEUTICS' INVESTIGATIONAL CELL THERAPY LEMIRETPROCEL (OPCT-001) FOR PRIMARY PHOTORECEPTOR DISEASES GRANTED ORPHAN DRUG DESIGNATIONS BY FDA AND EMA
Further company coverage: [BAYGn.DE]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women